<a href="https://www.fiercebiotech.com/medtech/ada-dexcom-cgm-shows-benefit-non-insulin-diabetes-patients" hreflang="en">ADA: Dexcom CGM shows benefit in non-insulin diabetes patients</a>
A recent study presented at the American Diabetes Association's 2026 Scientific Sessions found that a Dexcom continuous glucose monitor (CGM) significantly improved blood sugar control in adults with type 2 diabetes not using insulin, with 82% of participants showing improved glucose levels over six months. The findings support the potential for broader CGM use in primary care, although challenges remain regarding insurance coverage for non-insulin users.
The CONNECT trial demonstrates that Dexcom's G7 continuous glucose monitor (CGM) significantly improves blood sugar control in non-insulin-using type 2 diabetes patients, showing a 0.9-percentage-point greater reduction in A1C compared to routine care. This finding could expand the application of CGMs in primary care settings, providing an actionable opportunity to address care gaps in type 2 diabetes management. However, broader adoption hinges on proving long-term benefits and gaining payer coverage beyond insulin-dependent users.